RPL17 and lung cancer: Immunotherapy, including cell Programmed Death 1 (PD- 1), Programmed Death- Ligand 1(PD-L1), and Cytotoxic T- Lymphocyte Antigen- 4 (CTLA-4) inhibitors, has been an effective treatment for lung cancer in the last few years.